drugset
drugset / Trial / NCT06932536

The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Formulation F1) in Healthy Volunteers

NCT06932536 ↗

Phase 1 Completed 40 enrolled Shanghai SIMR Biotechnology Co., Ltd.
RandomizedSequentialTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, safety and tolerability of SR750 (formulation F1) in Chinese healthy subjects.

Timeline

Start
2025-04-28
Primary completion
2025-07-07
Completion
2025-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SR750 Unknown 30 mg Oral
Subject SR750 Unknown 60 mg Oral
Subject SR750 Unknown 100 mg Oral

Indications

No indication recorded.